Until recently, the primary Food and Drug Administration (FDA)-approved treatment for Alzheimer’s disease focused only on symptoms and relied on acetylcholinesterase inhibitors such as rivastigmine, donepezil, and galantamine, in addition to memantine, an NMDA antagonist [3]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.